- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02390063
Vaccination in Prostate Cancer (VANCE)
A Randomized Phase I Study to Determine the Safety and Immunogenicity of ChAd-MVA Vaccination Compared to MVA Alone With and Without Low Dose Cyclophosphamide in Low and Intermediate Risk Localised Prostate Cancer
This is a clinical trial of a new treatment for prostate cancer that is a type of vaccine that could be a new way to treat cancer. A vaccine that could alert the immune system to the presence of cancer cells in the body may enable the immune system to target and kill those cells effectively. This vaccine is intended to work by making the immune system kill cells that have a special protein (called 5T4) that is present on the surface of cancer cells. The vaccine is made up of two recombinant viruses ("ChAdOx1" and "MVA") that have been designed to produce the 5T4 protein and have been modified so that they are weakened and cannot reproduce themselves within the body like normal viruses. Once injected into the body, these viruses make the 5T4 protein and help the body's immune system to learn to target this protein and destroy cancer cells.
This is a first-in-human study to evaluate the safety and immunogenicity of ChAdOx1.5T4-MVA.5T4 vaccination regime. It is evaluated in neo-adjuvant setting in low and intermediate risk localised prostate cancer patients who have either decided to have their prostate removed or are stable on active surveillance.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Oxford, United Kingdom, OX3 7DQ
- University of Oxford
-
Sheffield, United Kingdom, S10 2IF
- Royal Hallamshire Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria(Radical Prostatectomy patients):
- Males aged 18 years and older
- Histologically confirmed prostate cancer diagnosed on biopsy within 6 months
Clinically localised, low or intermediate risk prostate cancer, i.e.:
- Gleason score ≤ 7
- Local tumour stage ≤T2c
- No evidence of metastases (Nx/N0 and Mx/M0)
- PSA ≤ 20 ng/ml
- Scheduled for and considered fit for radical prostatectomy
- Absence of any indication to perform urgent surgery that would not allow administration of the vaccine during the 12 week period prior to radical prostatectomy
- No invasive treatment for prostatic disease within the last 2 years
- Subject is free of clinically apparent/active autoimmune disease (no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave's Disease, Hashimoto's Thyroiditis, Multiple Sclerosis, and Insulin Dependent Diabetes Mellitus). Note subjects with Non-Insulin Dependent Diabetes Mellitus can be included.
- Subject has adequate bone marrow function as defined by an Absolute Lymphocyte Count (ALC) ≥ 500/µL, Absolute Neutrophil Count (ANC) >1200/µL, Platelet Count >100,000/µL.
- Subject must practice a reliable form of contraception (barrier or vasectomy) while they are being treated with vaccines and another effective method of birth control must also be used by their partner
Inclusion Criteria (Active Surveillance patients)
- Males aged 18 and older
- Histologically confirmed prostate cancer diagnosed on biopsy within 6 months
Clinically localised, low or intermediate risk prostate cancer, i.e.:
- Gleason score ≤ 7
- Local tumour stage ≤T2c
- No evidence of metastases (Nx/N0 and Mx/M0)
- PSA ≤ 20 ng/ml
- Stable disease on Active Surveillance for a minimum of 12 months previously
- Suitable to remain on Active Surveillance at time of last clinical assessment
- No invasive treatment for prostatic disease within the last 2 years
- Subject is free of clinically apparent/active autoimmune disease (no prior confirmed diagnosis or treatment for autoimmune disease including Systemic Lupus Erythematosis, Grave's Disease, Hashimoto's Thyroiditis, Multiple Sclerosis, and Insulin Dependent Diabetes Mellitus). Note subjects with Non-Insulin Dependent Diabetes Mellitus can be included.
- Subject has adequate bone marrow function as defined by an Absolute Lymphocyte Count (ALC) ≥ 500/µL, Absolute Neutrophil Count (ANC) >1200/µL, Platelet Count >100,000/µL.
- Subject must practice a reliable form of contraception (barrier or vasectomy) while they are being treated with vaccines and another effective method of birth control must also be used by their partner
Exclusion Criteria:
- Diagnosis of any cancer other than prostate cancer within the last 5 years (except basal cell carcinoma)
- Any suspicion of metastatic cancer
- Any Gleason grade 5 component in the prostatic biopsies
- Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period
- Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
- Seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) or HIV
- Any confirmed or suspected immunosuppressive or immunodeficient state, asplenia, recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled/topical steroids are allowed)
- Platelet count >400,000/μL; Monocytes >80,000/μL; Hemoglobin <11g/dL
- Known allergy to neomycin
- History of allergic response to previous vaccinia vaccinations
- History of allergic disease or reactions likely to be exacerbated by any component of the vaccine, e.g. egg products
- History of hypersensitivity and haemorrhagic cystitis
- Any history of anaphylaxis
- Suspected or known current injecting drug or alcohol abuse (as defined by an alcohol intake of greater than 42 units per week)
- History of a serious psychiatric condition or other circumstance s that may be associated with not understanding or complying with the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CHAMVA standard regime
ChAdOx1.5T4 prime followed by two boost of MVA.5T4 vaccine at 4 week intervals until radical prostatectomy
|
A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
|
Experimental: CHAMVA+CTX standard regime
One week of low dose cyclophosphamide pre-conditioning before each vaccination.
ChAdOx1.5T4
prime followed by two boost of MVA.5T4 at 4 week intervals until radical prostatectomy.
|
A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
Metronomic cyclophosphamide (50mg bd)
Other Names:
|
Active Comparator: MVA standard regime
Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
|
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
|
Active Comparator: MVA+CTX standard regime
One week of low dose cyclophosphamide pre-conditioning before each vaccination.Three MVA.5T4 vaccinations at 4 week intervals until radical prostatectomy
|
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
Metronomic cyclophosphamide (50mg bd)
Other Names:
|
Experimental: CHAMVA accelerated regime
ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
|
A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
|
Experimental: CHAMVA+CTX accelerated regime
One week of low dose cyclophosphamide pre-conditioning before each vaccination.
ChAdOx1.5T4
prime followed by one boost of MVA.5T4 one week later until radical prostatectomy.
|
A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
Metronomic cyclophosphamide (50mg bd)
Other Names:
|
Experimental: CHAMVA accelerated regime AS
ChAdOx1.5T4 prime followed by one boost of MVA.5T4 one week later.
Patients continue on active surveillance.
|
A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
|
Experimental: CHAMVA+CTX accelerated regime AS
One week of low dose cyclophosphamide pre-conditioning before each vaccination.
ChAdOx1.5T4
prime followed by one boost of MVA.5T4 one week later.
Patients continue on active surveillance.
|
A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
Metronomic cyclophosphamide (50mg bd)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaccine safety and immunogenicity
Time Frame: Up to 52 weeks
|
Development or increase in anti-5T4 cellular and humoral responses in patients treated with CHAMVA or CHAMVA + CTX
|
Up to 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cellular and humoral immune response with CHAMVA
Time Frame: Up to 52 weeks
|
Development or increase in anti-5T4 cellular and humoral responses in patients treated with the CHAMVA vaccination regimes
|
Up to 52 weeks
|
Cellular and humoral immune response with MVA
Time Frame: Up to 52 weeks
|
Development or increase in anti-5T4 cellular and humoral response in patients treated with the MVA vaccination regimes.
|
Up to 52 weeks
|
PSA level change secondary to vaccination
Time Frame: Participants will be followed for the duration of the study, up to 52 weeks
|
PSA level decrease in patients treated with CHAMVA or MVA vaccination at week 4,8 or 12.
|
Participants will be followed for the duration of the study, up to 52 weeks
|
MRI or Gleason score change secondary to vaccination
Time Frame: Participants will be followed for the duration of the study, up to 52 weeks
|
Reduction of tumour burden or Gleason score at weeks 4, 8 or 12.
|
Participants will be followed for the duration of the study, up to 52 weeks
|
Regulatory T-cell response
Time Frame: Participants will be followed for the duration of the study, up to 52 weeks
|
Change in the frequency of regulatory T-cells measured in blood or tumour samples from patients treated with metronomic cyclophosphamide compared to patients not receiving cyclophosphamide
|
Participants will be followed for the duration of the study, up to 52 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Freddie Hamdy, Oxford University Hospitals NHS Trust
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
Other Study ID Numbers
- VANCE01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States